Abstract:Pleomorphic adenoma is the most common benign tumor of the salivary glands tumors. First line treatment for this tumor is surgical excision and adjuvant radiotherapy was reported being applied to recurrent pleomorphic adenoma with high risk of recurrence. The aim of this study was to discuss the safety and treatment efficacy of (125) I seed interstitial brachytherapy for recurrent pleomorphic adenoma and propose the method to solve the clinical difficulty. Patients with recurrent pleomorphic adenoma of head and neck were included if the tumor cannot achieve complete resection with high risk of facial paralysis or high incidence of recurrence after operation. Patients were excluded if the tumor can achieve completely resection, risk and quality of life after surgery can be accepted, the patient had other malignant tumor history or were medically inoperable. The patients were performed CT and MRI used to develop the (125) I brachytherapy Plan in brachytherapy treatment planning system. The planning target volume (PTV) margin was designed matching the tumor margin. With 3D printing Individual template, CT or surgical navigation system guidance (125) I seed implantation was performed. Post-operation CT used to develop quality verification. The matched peripheral dose (MPD) was ranging from 110 to 140Gy. CT, MRI and biopsy were applied to evaluate treatment efficacy. From June 2012 to October 2015, 12 patients with recurrent pleomorphic adenoma were treated with (125) I seed brachytherapy alone (12 patients) or combined with surgery (1 patients), with follow-up ranging from 6 to 40 months (median, 15 months). Primary site of 13 patients was all parotid gland. Recurrent site of 8 patients were parotid gland while 3 were buccal and 2 were skull base. Patients accepted previous surgery from 1 to 4 times (median, 2.6 times) and 9 of 13 patients presented multinodular recurrence. 6 patients (50%) with 140Gy MPD reached complete response and 6 patients (50%) with 110∼120Gy MPD reached partial response in the 12 brachytherapy alone patients. The 6 patients also reached complete response 6 months after receiving the second time brachytherapy while nodules less than 1cm were all regression after the first time brachytherapy. 1 patient with adjuvant brachytherapy was no sign of tumor. 13 patients were locally controlled and facial nerve function was all preserved. No severe toxicities were observed. Preliminary results of this study showed 125I seed interstitial brachytherapy for recurrent pleomorphic adenoma presented excellent treatment efficacy which provided a safe and minimally invasive method avoiding the risk of facial paralysis brought by reoperation. Planning target volume and prescription dose could be optimized based on clinical and pathological features of recurrent pleomorphic adenoma and the size of tumor. Radiobiology and dosimetry problems about low-dose-rate brachytherapy for recurrent pleomorphic adenoma need further research.

[125I seed implant brachytherapy of recurrent parotid gland malignant tumor].

Brachytherapy for Recurrent Malignant Tumours of the Parotid Gland.

125I Seed Implant Brachytherapy-Assisted Surgery with Preservation of the Facial Nerve for Treatment of Malignant Parotid Gland Tumors

Preliminary Study of Treating Parotid Gland Malignant Tumor with Saving Facial Nerve (surgery Associated with 125I Seed Implant Brachytherapy)

Preliminary Results of (125)I Interstitial Brachytherapy for Locally Recurrent Parotid Gland Cancer in Previously Irradiated Patients.

Clinical analysis of 125Ⅰ brachytherapy alone for 24 recurrent parotid gland carcinoma

Conservative parotidectomy combined with brachytherapy for parotid gland carcinoma

Radioactivity Seeds Interstitial Brachtherapy Treating Malignant Salivary Gland Tumors

Surgery combined with 125I seed implantation brachytherapy for treatment of malignant submandibular gland tumors

[Radioactive Seed Implantation in Treatment of Oral and Maxillofacial Malignancy].

Postoperative [I-125] Seed Brachytherapy In The Treatment Of Acinic Cell Carcinoma Of The Parotid Gland With Associated Risk Factors

(125)I Seed Interstitial Brachytherapy for Recurrent Pleomorphic Adenoma

[Ultrasound Guided Implantation of Radioactive (125)I Seeds for Treatment of Recurrent Head and Neck Carcinomas].

Implantation of 125Ⅰ seeds for recurrence cervical node of head and neck tumor after external beam radiotherapy

An Investigation of 125I Seed Permanent Implantation for Recurrent Carcinoma in the Head and Neck after Surgery and External Beam Radiotherapy

Permanent Implantation of 125I Seeds As a Salvage Therapy for Head and Neck Carcinoma after Radiotherapy

Efficacy of radioactive 125I seed implantation in treating inoperable or refused operation head and neck cancers

125I Seed Implant Brachytherapy for the Treatment of Unresectable Parotid Gland Malignant Tumours in Children

[Short- to Mid-Term Evaluation of CT-guided 125I Brachytherapy on Recurrent or Metastatic Head and Neck Cancers].

CT-guided Implantation of Interstitial 125I Seed for Brachytherapy of Recurrent Head and Neck Tumor

Postoperative [ 125 I] Seed Brachytherapy in the Treatment of Acinic Cell Carcinoma of the Parotid Gland